Over a hot pot dinner in Shanghai in the fall of 2024, former I-Mab Biopharma executives Lei Fang and Jielun Zhu began to plot their next drug development startup.
AstraZeneca, Sanofi, AbbVie and Novartis will again face claims that they charged “unlawfully inflated prices” under the 340B drug discount program, after the case was dismissed in 2024.
Lantern, a company that helps employers manage what they spend on specialty care, raised $30 million as its client base broadens to include work with healthcare plans.
Johnson & Johnson secured an FDA approval on Wednesday for a psoriasis pill it expects to become a megablockbuster.
GSK’s recent deal to license out a rare liver disease drug just got sweeter.
Aspen Neuroscience said its experimental Parkinson's disease treatment, made from a patient's own cells, showed encouraging results in a small study.
Plus, news about Eledon, Sobi, Ovid and CytomX:
Verily has raised $300 million in new, outside funding that ends parent company Alphabet's controlling position in the healthcare innovation company, Endpoints News has learned exclusively.
TerraPower Isotopes, a subsidiary of founder Bill Gates' nuclear company TerraPower, is building an actinium-225 factory in Philadelphia. Production will start in 2029.